Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C91384
http://purl.obolibrary.org/obo/NCIT_C91384
|
|---|---|
| Preferred Name | Flanvotumab |
| Definitions |
A monoclonal antibody directed against the melanosomal membrane protein gp75 (or Tyrosinase-Related Protein 1 (TRP1)) with potential immunostimulatory and antineoplastic activities. Anti-gp75 monoclonal antibody IMC-20D7S targets and binds to gp75. This may lead to the induction of cytotoxic T cell immune and antibody-mediated immune responses against melanoma cells expressing gp75. gp75, a pigmentation-associated antigen, is expressed in melanosomes of human melanocytes and melanomas.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A monoclonal antibody directed against the melanosomal membrane protein gp75 (or Tyrosinase-Related Protein 1 (TRP1)) with potential immunostimulatory and antineoplastic activities. Anti-gp75 monoclonal antibody IMC-20D7S targets and binds to gp75. This may lead to the induction of cytotoxic T cell immune and antibody-mediated immune responses against melanoma cells expressing gp75. gp75, a pigmentation-associated antigen, is expressed in melanosomes of human melanocytes and melanomas. |
|---|---|
| prefLabel | Flanvotumab
|
| label | Flanvotumab
|
| NCI_META_CUI | CL421598
|
| PDQ_Closed_Trial_Search_ID | 675217
|
| code | C91384
|
| prefixIRI | NCIT:C91384
|
| in_subset |
See more
See less
|
| Display_Name | Flanvotumab
|
| Preferred_Name | Flanvotumab
|
| FDA_UNII_Code | ZNV4738BS6
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Flanvotumab
|
| CAS_Registry | 1188277-05-5
|
| NCI_Drug_Dictionary_ID | 675217
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 675217
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |